Founded in 2020 by Alex Federation, PhD, and Lindsay Pino, PhD, Talus Bio is a drug discovery and development company focused on therapeutics that target previously undruggable transcription factors. The Seattle-based company's proprietary therapeutics discovery platform, MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors), integrates AI, next-gen proteomics, synthetic chemistry, and computational biology to engineer and interrogate drugs, proteins, and genomics at unprecedented scale. Talus Bio employs a growing team of more than a dozen world-leading experts in proteomics, biochemistry, computational biology, and machine learning.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/20/24 | $11,200,000 | Seed+ |
BoxOne Ventures FundersClub NFX Two Bear Capital  WRF Capital Y Combinator | undisclosed |
